|
|||||
|
|
ACT001 can prevent and reverse tamoxifen resistance in human breast cancer cell lines by inhibiting NF-κB activation |
|
| Authors: | Xiao-Han Jin Yong-Sheng Jia Ye-Hui Shi Qiu-Ying Li Shi-Qi Bao Wen-Ping Lu Zhong-Sheng Tong |
| Institution: | 1. Department of Breast Oncology, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Ministry of Education, Tianjin Medical University, Tianjin, China;2. Department of Breast Oncology, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Ministry of Education, Tianjin Medical University, Tianjin, China
Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin, China Tianjin's Clinical Research Center for Cancer, Tianjin, China;3. State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, Nankai University, Tianjin, China Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin, China;4. Accendatech Co, Ltd, Tianjin, China;5. Oncology Department, Guang'anmen Hospital, Beijing, China |
| Abstract: | |
| Keywords: | ACT001 apoptosis breast neoplasms endocrine therapy nuclear factor-κB tamoxifen resistance |